{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:49:35Z","timestamp":1776199775054,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T00:00:00Z","timestamp":1620345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The incidence of hydrocephalus in the spinal muscular atrophy (SMA) population relative to the general population is currently unknown. Since the approval of nusinersen, an intrathecally administered drug for SMA, a small number of hydrocephalus cases among nusinersen users have been reported. Currently, the incidence of hydrocephalus in untreated SMA patients is not available, thereby making it difficult to determine if hydrocephalus is a side effect of nusinersen or part of SMA\u2019s natural history. This retrospective, matched cohort study used electronic health records (EHRs) to estimate and compare the incidence of hydrocephalus in both SMA patients and matched non-SMA controls in the time period prior to the approval of nusinersen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The U.S. Optum\u00ae de-identified EHR database contains records for approximately 100 million persons. The current study period spanned January 1, 2007\u2013December 22, 2016. Patients with SMA were identified by one or more <jats:italic>International Classification of Diseases (ICD)-9<\/jats:italic> and\/or <jats:italic>ICD-10<\/jats:italic> codes for SMA appearing as primary, admission, or discharge diagnoses, without a pregnancy diagnostic code in the 1-year time before and after the first occurrence of SMA. The first occurrence of SMA defined the index date and non-SMA controls were matched to cases. Incident cases of hydrocephalus were identified with one or more <jats:italic>ICD-9<\/jats:italic> and\/or <jats:italic>ICD-10<\/jats:italic> code for any type of hydrocephalus following the index date. Hydrocephalus incidence rates per person-months and the incidence rate ratio comparing SMA cases with non-SMA controls were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 5354 SMA cases and an equal number of\u00a0matched non-SMA controls. Incident hydrocephalus events were identified in 42 SMA cases and 9 non-SMA controls. Hydrocephalus incidence rates per 100,000 person-months were 15.5 (95% CI: 11.2\u201320.9) among SMA cases and 3.3 (95% CI: 1.5\u20136.3) among non-SMA controls. The incidence rate ratio was 4.7 (95% CI: 2.4\u201310.2).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Based on this retrospective analysis utilizing US EHR data, SMA patients had an approximately fourfold increased risk of hydrocephalus compared with non-SMA controls in the era preceding nusinersen treatment. This study may assist in properly evaluating adverse events in nusinersen-treated SMA patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-01822-4","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T13:06:10Z","timestamp":1620392770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The incidence of hydrocephalus among patients with and without spinal muscular atrophy (SMA): Results from a US electronic health records study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-8216","authenticated-orcid":false,"given":"Emma","family":"Viscidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maneesh","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishir","family":"Bhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Prada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayle","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie","family":"Lallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Makepeace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Laird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Dilley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,7]]},"reference":[{"key":"1822_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/B978-0-323-37101-8.00139-9","volume-title":"Swaiman's pediatric neurology: principles and practice","author":"BT Darras","year":"2017","unstructured":"Darras BT, Monani UR, De Vivo DC, et al. Genetic disorders affecting the motor neuron: spinal muscular atrophy. In: Swaiman KF, Ashwal S, Ferriero DM, et al., editors. Swaiman\u2019s pediatric neurology: principles and practice. 6th ed. Elsevier; 2017. p. 1057\u201364.","edition":"6"},{"issue":"1","key":"1822_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2011.09.001","volume":"46","author":"JA Markowitz","year":"2012","unstructured":"Markowitz JA, Singh P, Darras BT. Spinal muscular atrophy: a clinical and research update. Pediatr Neurol. 2012;46(1):1\u201312.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"1822_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11(5):443\u201352.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1822_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/ejhg.2011.134","volume":"20","author":"EA Sugarman","year":"2012","unstructured":"Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z, Rohlfs EM, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27\u201332.","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"1822_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1111\/j.1651-2227.2008.01201.x","volume":"98","author":"E Arkblad","year":"2009","unstructured":"Arkblad E, Tulinius M, Kroksmark AK, Henricsson M, Darin N. A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatr. 2009;98(5):865\u201372.","journal-title":"Acta Paediatr"},{"issue":"3","key":"1822_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000275492","volume":"34","author":"M Jedrzejowska","year":"2010","unstructured":"Jedrzejowska M, Milewski M, Zimowski J, Zagozdzon P, Kostera-Pruszczyk A, Borkowska J, et al. Incidence of spinal muscular atrophy in Poland\u2014more frequent than predicted? Neuroepidemiology. 2010;34(3):152\u20137.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"1822_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","volume":"12","author":"C Lally","year":"2017","unstructured":"Lally C, Jones C, Farwell W, Reyna SP, Cook SF, Flanders WD. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet J Rare Dis. 2017;12(1):175.","journal-title":"Orphanet J Rare Dis"},{"issue":"Pt 11","key":"1822_CR8","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1093\/brain\/awp236","volume":"132","author":"FL Norwood","year":"2009","unstructured":"Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain. 2009;132(Pt 11):3175\u201386.","journal-title":"Brain"},{"issue":"10020","key":"1822_CR9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0140-6736(15)60694-8","volume":"387","author":"KT Kahle","year":"2016","unstructured":"Kahle KT, Kulkarni AV, Limbrick DD Jr, Warf BC. Hydrocephalus in children. Lancet. 2016;387(10020):788\u201399.","journal-title":"Lancet"},{"key":"1822_CR10","unstructured":"Koleva M, De Jesus O. Hydrocephalus. In: StatPearls. StatPearls Publishing LLC; 2020. https:\/\/www.ncbinlmnihgov\/books\/NBK560875\/."},{"key":"1822_CR11","unstructured":"Fishman MA. Hydrocephalus. In: Neurological pathophysiology. Oxford; 1978."},{"key":"1822_CR12","unstructured":"Carey CM, Tullous MW, Walker ML. Hydrocephalus: etiology, pathologic effects, diagnosis, and natural history. In Pediatric neurosurgery, 3rd ed. WB Saunders Company; 1994."},{"key":"1822_CR13","unstructured":"Das JM, Biagioni MC. Normal pressure hydrocephalus. In: StatPearls; https:\/\/www.ncbinlmnihgov\/books\/NBK560875\/. Treasure Island, FL: StatPearls Publishing LLC.; 2020."},{"issue":"10","key":"1822_CR14","doi-asserted-by":"publisher","first-page":"e0204926","DOI":"10.1371\/journal.pone.0204926","volume":"13","author":"AM Isaacs","year":"2018","unstructured":"Isaacs AM, Riva-Cambrin J, Yavin D, Hockley A, Pringsheim TM, Jette N, et al. Age-specific global epidemiology of hydrocephalus: systematic review, metanalysis and global birth surveillance. PLoS ONE. 2018;13(10):e0204926-e205026.","journal-title":"PLoS ONE"},{"key":"1822_CR15","unstructured":"Biogen. SPINRAZA (nusinersen) [Prescribing Information] injection, for intrathecal use. 2018. www.spinraza.com\/content\/dam\/commercial\/specialty\/spinraza\/caregiver\/en_us\/pdf\/spinraza-prescribing-information.pdf."},{"issue":"Suppl 4","key":"1822_CR16","first-page":"S282","volume":"5","author":"SA Shohoud","year":"2014","unstructured":"Shohoud SA, Azab WA, Alsheikh TM, Hegazy RM. Blake\u2019s pouch cyst and Werdnig\u2013Hoffmann disease: report of a new association and review of the literature. Surg Neurol Int. 2014;5(Suppl 4):S282\u20138.","journal-title":"Surg Neurol Int"},{"issue":"3","key":"1822_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.braindev.2019.12.006","volume":"42","author":"T Tozawa","year":"2020","unstructured":"Tozawa T, Kasai T, Tatebe H, Shiomi K, Nishio H, Tokuda T, et al. Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: a case report focusing on the neurofilament light chain in cerebrospinal fluid. Brain Dev. 2020;42(3):311\u20134.","journal-title":"Brain Dev"},{"issue":"3","key":"1822_CR18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/ana.25549","volume":"86","author":"RH Mendon\u00e7a","year":"2019","unstructured":"Mendon\u00e7a RH, Rocha AJ, Lozano-Arango A, Diaz AB, Castiglioni C, Silva AMS, et al. Severe brain involvement in 5q spinal muscular atrophy type 0. Ann Neurol. 2019;86(3):458\u201362.","journal-title":"Ann Neurol"},{"issue":"11","key":"1822_CR19","first-page":"e11433","volume":"12","author":"FZ Alkhars","year":"2020","unstructured":"Alkhars FZ, Almajhad N, Al-Obaid J, Alghadeer F, Bo Ali AY. Spinal muscular atrophy and communicating hydrocephalus: a novel or a well-established rare association? Cureus. 2020;12(11):e11433.","journal-title":"Cureus"},{"issue":"10","key":"1822_CR20","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1177\/0883073817712589","volume":"32","author":"E Stambolliu","year":"2017","unstructured":"Stambolliu E, Ioakeim-Ioannidou M, Kontokostas K, Dakoutrou M, Kousoulis AA. The most common comorbidities in Dandy\u2013Walker Syndrome patients: a systematic review of case reports. J Child Neurol. 2017;32(10):886\u2013902.","journal-title":"J Child Neurol"},{"issue":"10","key":"1822_CR21","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00381-011-1544-4","volume":"27","author":"P Spennato","year":"2011","unstructured":"Spennato P, Mirone G, Nastro A, Buonocore MC, Ruggiero C, Trischitta V, et al. Hydrocephalus in Dandy\u2013Walker malformation. Childs Nerv Syst. 2011;27(10):1665\u201381.","journal-title":"Childs Nerv Syst"},{"issue":"1","key":"1822_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4103\/1817-1745.131488","volume":"9","author":"G Gathwala","year":"2014","unstructured":"Gathwala G, Silayach J, Bhakhari BK, Narwal V. Very severe spinal muscular atrophy: type 0 with Dandy\u2013Walker variant. J Pediatr Neurosci. 2014;9(1):55\u20136.","journal-title":"J Pediatr Neurosci"},{"issue":"8","key":"1822_CR23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1136\/jnnp.2004.055855","volume":"76","author":"M Panas","year":"2005","unstructured":"Panas M, Spengos K, Tsivgoulis G, Kalfakis N, Sfagos C, Vassilopoulos D, et al. Spinal muscular atrophy, Dandy\u2013Walker complex, and cataracts in two siblings: a new entity? J Neurol Neurosurg Psychiatry. 2005;76(8):1183\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"1822_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"8","key":"1822_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ejmg.2014.06.002","volume":"57","author":"HM Tully","year":"2014","unstructured":"Tully HM, Dobyns WB. Infantile hydrocephalus: a review of epidemiology, classification and causes. Eur J Med Genet. 2014;57(8):359\u201368.","journal-title":"Eur J Med Genet"},{"key":"1822_CR26","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1721131","author":"JP Sah","year":"2020","unstructured":"Sah JP, Abrams AW, Chari G, Linden C, Anziska Y. Hydrocephalus in spinal muscular atrophy: a case report and review of the literature. J Pediatr Neurol. 2020. https:\/\/doi.org\/10.1055\/s-0040-1721131.","journal-title":"J Pediatr Neurol."},{"issue":"2","key":"1822_CR27","first-page":"1012","volume":"2","author":"R Falsaperla","year":"2019","unstructured":"Falsaperla R, Wenzel A, Raudino G, Sframeli M, Gagliano C, Mazzeo A, et al. Intrathecal administration of nusinersen in patients with SMA1: too little is known. Neurol Case Rep. 2019;2(2):1012.","journal-title":"Neurol Case Rep."},{"issue":"10","key":"1822_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1212\/WNL.0000000000008074","volume":"93","author":"JI Takanashi","year":"2019","unstructured":"Takanashi JI, Takase N. Reader response: Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2019;93(10):464.","journal-title":"Neurology"},{"key":"1822_CR29","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723\u201332.","journal-title":"N Engl J Med"},{"issue":"21","key":"1822_CR30","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92(21):e2492\u2013506.","journal-title":"Neurology"},{"issue":"11","key":"1822_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356.","journal-title":"Neuromuscul Disord"},{"issue":"10063","key":"1822_CR32","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1822_CR33","first-page":"S185","volume":"29","author":"TO Crawford","year":"2020","unstructured":"Crawford TO, Ryan MM, Kirschner J, Finkel RS, Swoboda KJ, De Vivo DC, et al. Nusinersen in infants who initiate treatment in a presymptomatic stage of spinal muscular atrophy: interim results from the phase 2 NURTURE study. Neuromuscul Disord. 2020;29(Suppl 1):S185.","journal-title":"Neuromuscul Disord."},{"issue":"S121","key":"1822_CR34","first-page":"257","volume":"30","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Darras B, Chiriboga C, Farrar M, Kirschner J, Kuntz N, et al. Longer-term treatment with nusinersen: results in later-onset spinal muscular atrophy from the SHINE study. Neuromuscul Disord. 2020;30(S121):257.","journal-title":"Neuromuscul Disord"},{"issue":"S124","key":"1822_CR35","first-page":"266","volume":"30","author":"R Finkel","year":"2020","unstructured":"Finkel R, Castro D, Farrar M, Tulinius M, Krosschell K, Saito K, et al. Nusinersen in infantile-onset spinal muscular atrophy: results from longer-term treatment from the open-label SHINE extension study. Neuromuscul Disord. 2020;30(S124):266.","journal-title":"Neuromuscul Disord"},{"issue":"S120","key":"1822_CR36","first-page":"254","volume":"30","author":"B Darras","year":"2020","unstructured":"Darras B, Day J, Swoboda K, Chiriboga C, Iannaccone S, De Vivo D, et al. Nusinersen in adolescents and young adults with SMA: longitudinal experience from an expanded cohort of CS2\/CS12 and SHINE participants Neuromuscul Disord. 2020;30(S120):254.","journal-title":"Neuromuscul Disord."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01822-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01822-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01822-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T13:10:43Z","timestamp":1620393043000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01822-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,7]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1822"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01822-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,7]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. Emma Viscidi, Nasha Wang, Corinne Makepeace, Karen Laird, and\u00a0Susan Eaton are employees of Biogen and hold Biogen stock\/stock options.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}